← All trials
NCT03828201
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2020
- Primary completion
- Jan 31, 2024
- Completion date
- Jan 31, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Boston UniversityLead sponsor
- Boston UniversityOverall official - principal investigator
- Boston UniversityReponsible party - principal investigator
- Harvard UniversityCollaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- NovartisCollaborator
- OtsukaCollaborator
- PfizerCollaborator
- University of California, San FranciscoCollaborator
- University of California, San FranciscoOverall official - principal investigator
- University of Colorado, DenverCollaborator
- WestatCollaborator
- Boston UniversitySponsor investigator
- University of California, San FranciscoOfficial
- Boston UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.